Intellia Therapeutics (NTLA) Cash & Equivalents (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Cash & Equivalents for 12 consecutive years, with $134.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 6.16% year-over-year to $134.7 million; the TTM figure through Mar 2026 stood at $134.7 million (up 6.16% YoY), while the FY2025 annual figure was $155.5 million, down 17.82% from the prior year.
• Cash & Equivalents fell to $134.7 million in Q1 2026 per NTLA's latest filing, from $155.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $294.2 million in Q1 2023 and bottomed at $12.0 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $147.9 million across 5 years, with a median of $147.8 million in 2022.
• On a YoY basis, Cash & Equivalents climbed as much as 1796.36% in 2023 and fell as far as 91.91% in 2023.
• Intellia Therapeutics' Cash & Equivalents stood at $12.0 million in 2022, then jumped by 1796.36% to $226.7 million in 2023, then slipped by 16.57% to $189.2 million in 2024, then slipped by 17.82% to $155.5 million in 2025, then declined by 13.36% to $134.7 million in 2026.
• Business Quant data shows NTLA's Cash & Equivalents at $134.7 million in Q1 2026, $155.5 million in Q4 2025, and $193.4 million in Q3 2025.